Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | TP53 R158G |
Therapy | Gedatolisib |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 R158G | lung non-small cell carcinoma | sensitive | Gedatolisib | Preclinical | Actionable | In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human non-small cell lung carcinoma cells harboring TP53 R158G in culture (PMID: 21325073, PMID: 23980093). | 21325073 23980093 |
PubMed Id | Reference Title | Details |
---|---|---|
(21325073) | Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. | Full reference... |
(23980093) | Integrative radiogenomic profiling of squamous cell lung cancer. | Full reference... |